The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - The Christie Private Care
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; F. Hoffmann LaRoche; Merck Sharp & Dohme; Novartis; Pfizer; Takeda
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - F. Hoffmann LaRoche; Lilly; Merck Sharp & Dohme; Takeda
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
 
Jacob Sands
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Lilly; Medtronic; Takeda
Travel, Accommodations, Expenses - AstraZeneca
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb Foundation; Pfizer
Speakers' Bureau - AstraZeneca Spain; Roche
Expert Testimony - Medsir; Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Anne C. Chiang
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Flatiron Health; Genentech; Genentech; Genentech/Roche; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; Menarini; Pfizer; PrIME Oncology; Roche; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca; BMS; Hansoh; Hengrui Therapeutics; Hutchison MediPharma; Roche
 
Nir Peled
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Imagene AI; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer (Inst); Roche/Genentech (Inst)
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Hutchmed (I); Ipsen; Lilly; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Samuel J. Kerr
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Sanofi (Inst); Genentech (Inst); Merck (Inst)
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Alexey Smolin
Consulting or Advisory Role - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
 
Xinqun Chen
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Bin Zhao
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Hazem Edmond El-Osta
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Raffaele Califano
No Relationships to Disclose